EUROFINS SCIENTIFIC SE financials
EUROFINS SCIENTIFIC SE
Country: LU Reporting currency: EUR Latest annual report: 2024-12-31
LEI:
529900JEHFM47DYY3S57 Financial statements
(EUR, as reported — unscaled; 103 line items across 2 annual periods)
| Line item | 2024 | 2023 |
|---|---|---|
| Income statement | ||
| Revenue | €6.95B | €6.51B |
| Depreciation & amortisation | €596.9M | €565.0M |
| Operating profit (EBIT) | €680.5M | €529.9M |
| Finance costs | €151.2M | €129.8M |
| Profit before tax | €554.6M | €423.3M |
| Income tax expense | €149.1M | €115.5M |
| Profit for the year | €405.5M | €307.8M |
| — attributable to NCI | -€900.0K | -€2.5M |
| Total comprehensive income | €651.3M | €149.2M |
| Per share | ||
| Basic EPS | €2.13 | €1.61 |
| Diluted EPS | €2.09 | €1.57 |
| Free cash flow / share | €4.45 | €2.73 |
| Cash flow statement | ||
| Cash generated from operations | €1.48B | €1.16B |
| Net cash from operating activities | €1.32B | €1.02B |
| Income taxes paid | €160.7M | €139.7M |
| Net cash from investing activities | -€846.5M | -€681.1M |
| Purchase of PP&E (capex) | €453.6M | €478.1M |
| Net cash from financing activities | -€1.09B | €413.6M |
| Dividends paid | €98.0M | €193.1M |
| Proceeds from borrowings | €118.0M | €638.5M |
| Repayments of borrowings | €477.7M | €90.0M |
| Lease liability payments | €192.4M | €180.5M |
| Balance sheet | ||
| Total assets | €10.89B | €10.89B |
| Non-current assets | €8.44B | €7.82B |
| Property, plant & equipment | €2.56B | €2.30B |
| Intangible assets & goodwill | €4.84B | €4.55B |
| Current assets | €2.45B | €3.07B |
| Inventories | €141.9M | €139.0M |
| Trade & other receivables | €1.09B | €1.07B |
| Cash & equivalents | €613.9M | €1.22B |
| Total equity | €5.38B | €5.14B |
| — attributable to owners | €5.34B | €5.08B |
| Non-controlling interests | €45.8M | €59.9M |
| Non-current liabilities | €3.39B | €3.63B |
| Long-term borrowings | €3.13B | €3.33B |
| Current liabilities | €2.11B | €2.12B |
| Deferred tax liabilities | €109.5M | €110.0M |
| Derived metrics | ||
| Free cash flow | €865.3M | €539.8M |
| Operating margin | 9.8% | 8.1% |
| Net margin | 5.8% | 4.7% |
| Return on equity | 7.5% | 6.0% |
| Cash conversion ratio | 3.25× | 3.31× |
| Capex coverage | 2.91× | 2.13× |
| Other reported items | ||
| Adjusted Weighted Average Shares | 194.5M | 197.9M |
| Adjustments For Depreciation and Amortisation Expense | €596.9M | €565.0M |
| Adjustments For Finance Income Cost | -€126.4M | -€104.1M |
| Adjustments For Gain Loss On Disposal of Investments In Subsidiaries Joint Ventures and Associates | -€23.6M | -€1.8M |
| Adjustments For Undistributed Profits of Associates | €1.0M | €400.0K |
| Cash and Cash Equivalents If Different From Statement of Financial Position | €613.2M | €1.22B |
| Cash Flows From Losing Control of Subsidiaries Or Other Businesses Classified As Investing Activities | -€900.0K | €7.3M |
| Cash Flows Used In Obtaining Control of Subsidiaries Or Other Businesses Classified As Investing Activities | €343.4M | €158.1M |
| Comprehensive Income Attributable To Noncontrolling Interests | €100.0K | -€5.3M |
| Current Borrowings and Current Portion of Noncurrent Borrowings | €478.8M | €601.1M |
| Current Contract Assets | €306.2M | €307.7M |
| Current Contract Liabilities | €195.9M | €192.8M |
| Current Derivative Financial Assets | €2.0M | €4.3M |
| Current Provisions | €32.8M | €21.4M |
| Current Tax Assets Current | €101.8M | €118.3M |
| Current Tax Liabilities Current | €35.5M | €26.7M |
| Decrease Increase Through Tax On Sharebased Payment Transactions | €3.4M | €1.7M |
| Deferred Tax Assets | €130.3M | €93.8M |
| Dividends Proposed Or Declared Before Financial Statements Authorised For Issue But Not Recognised As Distribution To Owners | €115.8M | — |
| Dividends Proposed Or Declared Before Financial Statements Authorised For Issue But Not Recognised As Distribution To Owners Per Share | €0.60 | — |
| Dividends Recognised As Distributions To Owners Per Share | €1.00 | — |
| Effect of Exchange Rate Changes On Cash and Cash Equivalents | €9.4M | -€12.7M |
| Equity and Liabilities | €10.89B | €10.89B |
| Finance Income | €24.2M | €22.8M |
| Gains Losses On Cash Flow Hedges Before Tax | -€2.0M | -€900.0K |
| Gains Losses Recognised When Control In Subsidiary Is Lost | -€23.6M | -€1.8M |
| Income Tax Relating To Components of Other Comprehensive Income That Will Be Reclassified To Profit Or Loss | €0 | €0 |
| Income Tax Relating To Components of Other Comprehensive Income That Will Not Be Reclassified To Profit Or Loss | €4.2M | -€1.1M |
| Increase Decrease In Cash and Cash Equivalents | -€607.7M | €737.8M |
| Increase Decrease In Working Capital | -€43.9M | €64.8M |
| Increase Decrease Through Sharebased Payment Transactions | €21.8M | €23.3M |
| Increase Decrease Through Treasury Share Transactions | -€274.4M | -€55.8M |
| Intangible Assets Other Than Goodwill | €787.8M | €796.0M |
| Interest Paid Classified As Financing Activities | €114.2M | €82.2M |
| Interest Received Classified As Investing Activities | €19.4M | €11.6M |
| Investments In Associates Accounted For Using Equity Method | €5.9M | €5.3M |
| Issued Capital | €1.9M | €1.9M |
| Noncurrent Financial Assets | €111.5M | €78.3M |
| Noncurrent Provisions | €23.2M | €20.9M |
| Noncurrent Recognised Liabilities Defined Benefit Plan | €66.4M | €66.2M |
| Other Adjustments For Noncash Items | -€400.0K | €10.1M |
| Other Comprehensive Income | €245.8M | -€158.6M |
| Other Comprehensive Income Before Tax Exchange Differences On Translation | €156.4M | -€93.2M |
| Other Comprehensive Income Before Tax Gains Losses From Investments In Equity Instruments | €28.8M | -€1.6M |
| Other Comprehensive Income Before Tax Gains Losses On Remeasurements of Defined Benefit Plans | €5.5M | -€4.5M |
| Other Comprehensive Income Before Tax Hedges of Net Investments In Foreign Operations | €61.4M | -€59.5M |
| Other Comprehensive Income That Will Be Reclassified To Profit Or Loss Net of Tax | €215.8M | -€153.6M |
| Other Comprehensive Income That Will Not Be Reclassified To Profit Or Loss Net of Tax | €30.0M | -€5.0M |
| Other Current Liabilities | €621.0M | €584.8M |
| Other Operating Income Expense | -€5.51B | -€5.28B |
| Payments To Acquire Or Redeem Entitys Shares | €271.9M | €55.8M |
| Proceeds From Issuing Shares | €200.0K | €8.0M |
| Proceeds From Sales of Property Plant and Equipment Classified As Investing Activities | €10.2M | €6.4M |
| Reclassification Adjustments On Cash Flow Hedges Before Tax | €0 | €0 |
| Reserve of Exchange Differences On Translation | €351.7M | €135.8M |
| Retained Earnings | €2.69B | €2.39B |
| Share of Profit Loss of Associates Accounted For Using Equity Method | €1.0M | €400.0K |
| Trade and Other Current Payables To Trade Suppliers | €645.9M | €600.2M |
| Treasury Shares | €307.8M | €54.9M |
| Weighted Average Shares | 190.6M | 192.9M |
Methodology
Every line item above is a fact tagged in EUROFINS SCIENTIFIC SE's annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (EUR), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.